An unsuccessful clinical trial is not automatically cause for rescinding a drug or biologic’s breakthrough therapy designation, the US Food and Drug Administration said in a new draft guidance.
Rather, the decision to maintain or revoke breakthrough therapy status when subsequent results appear not to support the evidence on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?